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This is a qualitative review of the evidence linking dietary fat composition to the risk of developing
dementia. The review considers laboratory and animal studies that identify underlying mechanisms as
well as prospective epidemiologic studies linking biochemical or dietary fatty acids to cognitive decline
or incident dementia. Several lines of evidence provide support for the hypothesis that high saturated or
trans fatty acids increase the risk of dementia and high polyunsaturated or monounsaturated fatty acids
decrease risk. Dietary fat composition is an important factor in blood-brain barrier function and the
blood cholesterol proﬁle. Cholesterol and blood-brain barrier function are involved in the neuropa-
thology of Alzheimer’s disease, and the primary genetic risk factor for Alzheimer’s disease, apolipo-
protein E-ε4, is involved in cholesterol transport. The epidemiologic literature is seemingly inconsistent
on this topic, but many studies are difﬁcult to interpret because of analytical techniques that ignored
negative confounding by other fatty acids, which likely resulted in null ﬁndings. The studies that
appropriately adjust for confounding by other fats support the dietary fat composition hypothesis.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Dietary fat composition has been demonstrated to be important
in the prevention and treatment of cardiovascular diseases and
diabetes, conditions that have also been implicated as risk factors
for dementia (Appel et al., 2005; Furtado et al., 2008; Gadgil et al.,
2013). Therefore, it would appear reasonable that at the very least,
dietary fats would impact the brain through their effects on car-
diovascular conditions. This review describes the evidence to date
in support of dietary fat composition as a risk factor in the devel-
opment of dementia and will include laboratory studies, animal
models, and prospective epidemiologic studies. Whereas animal
and laboratory studies are emerging that suggest several biological
mechanisms underlying the relationship of fat composition to de-
mentia risk, the epidemiologic evidence is inconsistent. The study
of diet is complex and presents a number of analytical challenges.
Historically, the ﬁeld of nutrition has devoted limited attention to
neurodegenerative diseases. Thus, a number of studies have used
nutritionally unsophisticated analytical approaches that make it
difﬁcult to interpret the study ﬁndings. To give context to thisd Nutritional Epidemiology,
ical Center, 1725 W. Harrison,
0 2129; fax: þ1 312 942 563
orris).
Y-NC-ND license.discussion, we ﬁrst provide brief descriptions of the different types
of dementia and of dietary fats followed by a critical review of the
evidence.1.1. Dementia and Alzheimer’s disease
Dementia is an umbrella term for diseases that affect mental
abilities severely enough that the ability to perform tasks of daily
living is impaired (American Psychological Association, 2000).
Alzheimer’s disease (AD) is the primary form of dementia and
represents 60%e80% of cases (Bennett and Evans, 1992). Memory
loss is central to AD, along with impairment in one or more other
cognitive abilities, that is, visual perception, language ability,
reasoning, or attention (Bennett and Evans,1992). Some of themore
common forms of dementia are vascular dementia, dementia with
Lewy bodies, and mixed dementia. Few studies have reported on
the dietary relationship to vascular dementia or other rare de-
mentia diseases because of the limited number of incident cases in
cohort studies. Because the diagnosis of dementia and its various
forms is expensive and susceptible to bias, studies that relate risk
factors to a decline in cognitive abilities are important additions to
the literature. These types of investigations allow for much larger
populations to be studied at a fraction of the cost of clinical disease
evaluations. Further, they have the advantage of being less prone to
bias and allow for the testing of risk-factor relationships much
M.C. Morris, C.C. Tangney / Neurobiology of Aging 35 (2014) S59eS64S60earlier in the disease process (Morris et al., 1999). Factors that are
related to AD would also be expected to be related to cognitive
decline; however, the reverse is not a given because of the other
types of dementia that likely have different risk proﬁles. Also, de-
mentia pathologies account for <50% of the variance in the decline
in mental abilities with aging suggesting that there are causes of
decline other than these well-characterized dementia diseases
(Boyle et al., 2013). Included among these other causes of mental
decline are B-vitamin deﬁciencies, hypothyroidism, and depression.
1.2. AD brain pathology
The neuropathological features of AD include the extracellular
accumulation of amyloid-beta protein into neuritic plaques,
hyperphosphorylation of tau-protein to form neuroﬁbrillary tan-
gles within neuron cells, neuron loss, synapse loss, and brain at-
rophy (Schneider et al., 2009). One hypothesis is that oxidative
stress and inﬂammation are the underlying causal mechanisms of
AD pathology (Holmes, 2013; Mecocci et al., 1994). The blood-brain
barrier (BBB) protects the brain from environmental insults that
contribute to oxidative stress and inﬂammation. BBB dysfunction is
an early pathologic feature of AD and vascular dementia and can be
triggered by inﬂammatory stimuli (Takechi et al., 2012).
1.3. Lipids and the brain
Lipids are a class of molecules that comprises a number of sub-
classes, that is, triglycerides (composed of fatty acids linked to a
glycerol backbone), free fatty acids, sterols (cholesterol and
cholesterol-related compounds), phospholipids, and other groups of
compounds (Linscheer and Vergroesen, 1994). Lipids are the major
source of brain dry weight because they are the basic structural
component of neuronal cell membranes. Other important biological
functions of lipid molecules include energy storage and molecular
signaling (Linscheer and Vergroesen,1994). Cholesterolmay play an
important role in AD (Puglielli et al., 2003). Speciﬁcally, cholesterol
forms the core of the neuritic plaques that characterize AD, and it is
thought that a primary role of the amyloid precursor protein (APP) is
to clear excess cholesterol from the brain (Puglielli et al., 2003). The
most established genetic risk factor for AD is the apolipoprotein E
(APOE)-ε4 allele, which has been associated with nearly a doubling
in the risk of developing AD (Bennett et al., 2003; Evans et al., 1997).
ApoE encodes one of several proteins involved in cholesterol trans-
port between the gut, liver, and peripheral tissues and they are the
predominant cholesterol transport proteins in the brain. A number
of cohort studies that measured total blood cholesterol in midlife
found that participants with higher levels of total cholesterol or
hypercholesterolemia had an increased risk of developing dementia
in late life compared with the participants who had normal or low
cholesterol levels (Beydoun et al., 2010; Kivipelto et al., 2002;
Mainous et al., 2005; Notkola et al., 1998; Reynolds et al., 2010;
Solomon et al., 2007, 2009; Whitmer et al., 2005).
1.4. Dietary lipids
Fatty acid composition is characterized by both the degree of
unsaturation in the fatty acid chain and the conﬁguration about the
saturation. Fatty acid composition of the diet is one of the primary
factors that affect blood cholesterol levels. Speciﬁcally, high ratio of
unsaturated to saturated fatty acids results in a favorable blood
cholesterol proﬁle (Hunter, 1998). In contrast to the effects of fatty
acids on blood cholesterol, dietary cholesterol has a limited effect
and particularly in populations that consume a Western diet
(Hunter, 1998; Keys and Parlin, 1966; Mancini and Stamler, 2004).
Thus, this review is focused on noncholesterol-dietary lipids.The major categories of dietary fatty acids are saturated, trans,
monounsaturated, and polyunsaturated fatty acids. The dietary fatty
acids differ biochemically and are classiﬁed by the numbers of car-
bon atoms (length), the conﬁguration of hydrogen atoms around the
carbon-carbon double or triple bonds, and the position of unsatu-
ration from the methyl end of the hydrocarbon chain (Linscheer
et al.,1994). Food sources of fatty acids are products of bothplant and
animal origin. However, in humans, seeds and vegetable oils are the
sole source of the 2 essential fatty acids, a-linoleic acid (18:2 n-6),
and a-linolenic acid (18:3 n-3), which are polyunsaturated fatty
acids. These fatty acids are considered essential because they are
required for normal physiological function, cannot be synthesized
within thebody, andmust be consumed tomaintaingoodhealth. It is
important to note that dietary fatty acids are also required for the
adequate absorptionof the lipid soluble vitamins E, A,D, andKandof
the carotenoids. Many of these compounds function as antioxidants
that may be linked to brain health.
Saturated fatty acids have no double bonds and are solid at room
temperature (Linscheer et al., 1994). Most natural foods have
varying compositions of fatty acids, however, meat and dairy
products have a higher saturated fatty acid composition. Fruits and
vegetables tend to be lower in total fatty acids and the composition
is predominantly unsaturated. Trans fatty acids are made either by
microbial metabolism in ruminants or manufactured through the
hydrogenation of vegetable oil. In the hydrogenation process,
hydrogen is added to monounsaturated and polyunsaturated fatty
acid containing oils to make products such as margarine and
shortening. The process allows for the solidiﬁcation and enhanced
stability of these oils to mimic the properties of butter and lard.
Trans fatty acids improve the shelf life of food products and also can
improve food texture and ﬂavor. They are particularly hypercho-
lesterolemic because they both increase low density lipoprotein-
cholesterol and decrease high density lipoprotein-cholesterol
(Mozaffarian et al., 2009).
Throughout the mid to late1900s trans fatty acids were widely
consumed in the United States, particularly from manufactured
margarine products and baked goods. In the 1990s, scientiﬁc in-
vestigations linked trans fats to a higher risk of cardiovascular
disease (Teegala et al., 2009), which prompted legislation in 2006
requiring the identiﬁcation of the trans fatty acid content on food
labels. As a result of vigorous public health messaging about the
health risks of trans fats (i.e., partially hydrogenated vegetable oils)
and manufacturer’s reduction of trans fats in food products (most
probably in response to the labeling mandate), trans fatty acid
intake has decreased signiﬁcantly in the U.S. from a mean of 4.6 g/
d in 2003e2006 to 1.3 g/d in 2009 (Doell et al., 2012), which is a
decrease of 72%. Trans fatty acid consumption also differs markedly
by country and is historically low in the Netherlands and other
European countries (Michels and Sacks, 1995). Thus, depending on
a study’s historical period or country’s location, trans fatty acid
intake may be at a low level for the entire study population.
This review is focused on the broadest classes of fatty acids (i.e.,
saturated, trans, monounsaturated, and polyunsaturated) and does
not describe the large body of literature on the speciﬁc types of n-3
and n-6 polyunsaturated fatty acids that have been reviewed pre-
viously (Barberger-Gateau et al., 2011; Cole et al., 2010; Morris,
2012).
2. Review of evidence
2.1. Animal and laboratory studies of dietary fats
Most of the animal and laboratory research on dietary fatty acids
and the brain has occurred fairly recently and tends to support the
ﬁndings of the epidemiologic studies showing greater risk of
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risk with high unsaturated fatty acid intakes. Takechi et al. (2013)
have shown that a high-fat diet decreases the integrity of the BBB
and results in cerebrovascular inﬂammation in amyloid transgenic
mice fed either a high-saturated fatty acid diet (20% of energy) or a
high-cholesterol diet. After 12 weeks on the diets, the BBB
dysfunction of the mice on the high-saturated fatty acid diet was
increased 30-fold, whereas dysfunction on the high-cholesterol diet
was increased 7-fold. Mice who were also administered the lipid-
lowering agent, probucol, while on these diets experienced no
loss of BBB integrity or cerebrovascular inﬂammation, suggesting
that higher blood cholesterol concentration is central to BBB
dysfunction. In cell culture experiments, Grimm et al. (2012) found
that trans fatty acids increased amyloidogenic APP and decreased
non-amyloidogenic APP when comparedwith cis forms of oleic and
polyunsaturated fatty acids. Further, the trans fatty acids in this
study increased amyloid-beta (Ab) aggregation. Yet, another
investigation of transgenic mice found that greater concentrations
of Ab protein in the brain resulted from a westernized diet of 40%
saturated fatty acids over a 4-month period compared with a soy
oilebased diet (Oksman et al., 2006). Snigdha et al. (2012) con-
ducted a study on aged dogs inwhich they demonstrated that a diet
high in saturated fatty acids and low in monounsaturated fatty
acids increased learning errors and decreased cognitive perfor-
mance. Winocur and Greenwood (2005) found similar results inTable 1
Prospective studies of dietary fats and dementia
Study N Follow-up (y) Exposure Out
Ronnemaa et al. (2012), ULSAM 838 35 Serum AD
Samieri et al. (2008), 3-City 1214 4 Plasma Dem
Laitinen et al. (2006), CAIDE 1449 21 Diet (spreads) AD
Morris et al. (2003), CHAP 815 3.9 Diet AD
Engelhart et al. (2002), Rotterdam 5395 6 Diet AD
Dem
Luchsinger et al. (2002), WHICAP 980 4 Diet AD
Kalmijn et al. (1997), Rotterdam 5395 2 Diet AD
Vas
represents statistically signiﬁcant increased risk.
represents statistically signiﬁcant decreased risk.
represents marginally statistically signiﬁcant increased risk.
represents marginally statistically signiﬁcant decreased risk.
Key: AD, Alzheimer’s disease; CAIDE, Cardiovascular risk factors Aging and Incidence of
acids; PUFA, polyunsaturated fatty acids; ULSAM, Uppsala Longitudinal Study of Adult M
Columbia Aging Project.studies of transgenic mice spanning nearly 2 decades of research in
which impaired learning and memory performance resulted from
diets high in fat (40% of calories vs. 4.5% in standard chow) and
particularly diets high in saturated fatty acids. They concluded from
their studies that a chronic high-fat diet impairs glucose regulation
resulting in reduced glucose uptake in the hippocampus region of
the brain.
In summary, chronic feeding of saturated and trans fatty acids at
high levels to laboratory animals has been shown to result in BBB
dysfunction, increased Ab aggregation, poorer cognitive perfor-
mance, and reduced glucose usage in the key brain regions.
2.2. Epidemiologic studies of fats and cognitive decline
A number of prospective epidemiologic studies have investi-
gated the relationship of dietary fatty acid composition to the risk of
developing dementia (Table 1). A major challenge in the interpre-
tation of these studies is that most of them analyzed each type of
fatty acid in models that were not adjusted for other types of fatty
acids. Confounding is a likely explanation for the null results in
these studies because all the dietary fatty acids are moderately to
highly positively correlated with one another. For example, in the
Chicago Health and Aging Project (CHAP), dietary intake of mono-
unsaturated fatty acid was highly correlated with dietary intakes of
saturated fatty acids (r ¼ 0.82) and trans fatty acids (r ¼ 0.70), butcome Fats adjusted Saturated Trans MUFA PUFA U/S
d d
entia d d d
Yes
Yes
entia
No
d d
d
d
d
d
No d d
cular dementia
No d d
d
Dementia; CHAP, Chicago Health and Aging Project; MUFA, monounsaturated fatty
en; U/S, unsaturated to saturated fat ratio; WHICAP, Washington Heights-Inwood
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risk of AD and monounsaturated fatty acid was associated with a
decreased risk of AD (Morris et al., 2003). Failure to adjust for other
types of fatty acids in themodel resulted in negative confounding in
that the estimates of effect were smaller than the “true effect” or
closer to the null. The analyses of monounsaturated fatty acid intake
in the CHAP study indicated substantial negative confounding; the
estimated odds ratio (OR) of incident AD for persons in the top
quintile compared with the ﬁrst quintile was OR ¼ 0.8 without
adjustment for intakes of other fatty acids and OR ¼ 0.2 with
adjustment (Morris et al., 2003). Similarly, for the analyses of trans
fatty acids in the model without other fatty acids included, the OR
for intake quintiles 2e5 ranged from 1.8 to 2.9, and these increased
to 3.4e5.2 after the adjustment for other fatty acids.
The inclusion of all the highly correlated fatty acids in the
analytical model can be statistically problematic because of multi-
collinearity among the fatty acid variables, which can inﬂate the
standard errors of the estimates and thus lead to a failure to reject aTable 2
Prospective studies of dietary fats and cognitive decline
Study N Follow-up (y) Exposure Outco
Okereke et al. (2012), WHS 6183 9 Diet Globa
Roberts et al. (2012), Mayo 937 3.7 Diet MCI
Naqvi et al. (2011), WHI 482 3 Diet Globa
Vercambre et al. (2010), WACS 2551 8.9 Diet Globa
Devore et al. (2009), NHS 1486 1.8 Diet Globa
Eskelinen et al. (2008), CAIDE 1449 21 Diet MCI
Globa
Beydoun et al. (2007), ARIC 2251 6 Plasma Globa
Morris et al. (2006), CHAP 2560 6 Diet Globa
Solfrizzi et al., 2006, ULSAM 704 8.5 Diet MMSE
Heude et al. (2003), EVA 246 4.4 Erythrocytes MMSE
represents statistically signiﬁcant greater rate of cognitive decline.
represents statistically signiﬁcant slower rate of cognitive decline.
¼marginally statistically signiﬁcant slower rate of cognitive decline.
Key: ARIC, Atherosclerosis Risk in Community Studies; CAIDE, Cardiovascular risk factor
Etude du Vieillissement Artériel; Mayo, Mayo Clinic; MCI, mild cognitive impairment;
Nurses’ Health Study; PUFA, polyunsaturated fatty acids; ULSA, Uppsala Longitudinal Stud
Cardiovascular Study; WHI, Women’s Health Initiative; WHS, Women’s Health Study.false null hypothesis. The magnitude of this problem is greater for
studies with small sample size. In the CHAP study, saturated fatty
acid intake in the ﬁfth quintile was associated with double the risk
of incident AD compared with the ﬁrst quintile of intake (OR ¼ 2.2;
95% conﬁdence interval: 1.1e4.7) (Morris et al., 2003). With
adjustment for other types of fatty acids, the OR increased to 3.6
(indicating confounding by other fats) and the 95% conﬁdence in-
terval increased substantially (0.7e18.6) including the null value of
1 (indicating inﬂated standard error attributable to multi-
collinearity). The same problem of multicollinearity and inﬂated
standard errors with fatty acid adjustment was evident for the
other fats; the 95% conﬁdence interval (1.5e18.5) for the ﬁfth
quintile of trans fatty acid intake widened but was still statistically
signiﬁcant, whereas the 95% conﬁdence interval for mono-
unsaturated fatty acids was also very wide (0.2e1.5) and included
the null value. Dietary intake of n-6 polyunsaturated fatty acids was
linearly associated with a lower AD risk (Q5 vs. Q1 OR¼ 0.3, p-value
for linear trend ¼ 0.02) in the model without fat adjustment, butme Fats adjusted Saturated Trans MUFA PUFA U/S
l cognitive Yes d d
No d d d
l cognitive Partial d d
l cognitive Partial d d
l cognitive Yes d
l cognitive
Yes d
d d
d
d
l cognitive Yes d
l cognitive Yes
No d d
d d
s, Aging and Incidence of Dementia; CHAP, Chicago Health and Aging Project; EVA,
MMSE, Mini Mental State Examination; MUFA, monounsaturated fatty acids; NHS,
y of Adult Men; U/S, unsaturated to saturated fat ratio; WACS, Women’s Antioxidant
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nonsigniﬁcant (p ¼ 0.10). The nonsigniﬁcant OR in the adjusted
model is likely a result of the inﬂated standard error because of
multicollinearity given that the quintile effect estimates did not
change with and without the adjustment.
The only other incident dementia study, the Cardiovascular
Risk Factors, Aging and Dementia (CAIDE) study that adjusted for
all types of fatty acids in the analyses (Laitinen et al., 2006) had
somewhat similar ﬁndings to the CHAP study. In this study, only
the second quartiles of unsaturated fat and of saturated fatty
acids versus the ﬁrst quartiles of intake had a statistically sig-
niﬁcant relationship to late-life dementia. The authors inter-
preted this ﬁnding as evidence of nonlinear relationships of these
fatty acids with dementia. However, an alternative explanation is
that the fat intake assessment in this study likely had consider-
able measurement error because of the incomplete measurement
of fat intake. In this study, the respondents were only queried
about their use of diet spreads and milk products, thus, many
other sources of fat in the diet were not included in the assess-
ment of fat intake. Another important source of measurement
error was the single dietary assessment over 21 years of follow-
up (Laitinen et al., 2006). It is difﬁcult to interpret the ﬁndings
of the other studies of fatty acid intake and dementia (Table 1)
because other types of fatty acids were not accounted for in the
analyses.
Another method of analyzing fat composition is to model the
ratio of unsaturated to saturated fatty acid intake. In the CHAP
study, persons in the highest quintile of polyunsaturated to satu-
rated fatty acid intake (P/S median ¼ 0.9) had a statistically sig-
niﬁcant 70% reduction in the risk of developing AD over 3.9 years.
To the best of our knowledge, no other study of incident dementia
has investigated the relation of P/S ratio to dementia risk.
2.3. Epidemiologic studies of dietary fats and cognitive decline
Most studies that examined the relationship of dietary fat
composition to a decline in cognitive abilities adjusted for other
types of fatty acids in the analyses (Beydoun et al., 2007; Devore
et al., 2009; Eskelinen et al., 2008; Heude et al., 2003; Morris
et al., 2004; Okereke et al., 2012) or at least partially adjusted
for other fatty acids (Naqvi et al., 2011; Vercambre et al., 2010).
Those studies that adjusted for other fatty acids consistently
showed increased rates of cognitive decline with higher intakes of
saturated fatty acids. Further, in all but one of these studies,
decreased rates of cognitive decline were observed with higher
intakes of either monounsaturated fatty acids (Devore et al., 2009;
Morris et al., 2004; Naqvi et al., 2011; Okereke et al., 2012; Solfrizzi
et al., 2006; Vercambre et al., 2010) or polyunsaturated fatty acids
(Beydoun et al., 2007; Eskelinen et al., 2008; Morris et al., 2004;
Roberts et al., 2012; Solfrizzi et al., 2006; Vercambre et al.,
2010), although many of the associations were marginally statis-
tically signiﬁcant (indicated by gray arrows in Table 2) (Devore
et al., 2009; Eskelinen et al., 2008; Morris et al., 2004; Roberts
et al., 2012; Solfrizzi et al., 2006; Vercambre et al., 2010). Only 2
of the 5 studies (Devore et al., 2009; Eskelinen et al., 2008; Morris
et al., 2004; Solfrizzi et al., 2006; Vercambre et al., 2010) that
examined the relationship of the ratio of unsaturated to saturated
fatty acids (Devore et al., 2009; Morris et al., 2004) to cognitive
decline observed a decrease in the rate of decline. Among the
studies that adjusted for other types of fatty acids, trans fatty acid
intake was associated with a greater rate of decline in the CHAP
study (Morris et al., 2004) and among diabetics in the Nurses’
Health Study (Devore et al., 2009), however, there was no asso-
ciation in the Women’s Health Study (WHS) (Okereke et al., 2012).
One potential explanation for the null ﬁnding for trans fatty acidsin the WHS is that the intake levels were below the threshold to
affect the brain. Compared with the trans fatty acid intake levels in
the CHAP and Nurses’ Health Study (NHS), reported levels for the
WHS were very low at a median 1.8% of energy for the highest
quintile of intake.
3. Discussion
This review outlined several lines of evidence that support a
relationship between dietary fatty acid composition and the risk of
developing dementia. First, the composition of fatty acids in the diet
is one of the most important determinants of the blood cholesterol
proﬁle, and cholesterol plays a central role in AD pathology. Further,
the most important genetic risk factor for AD, APOE-ε4, is involved
in cholesterol transport, and the evidence from studies of midlife
blood cholesterol support a relationship of increased risk of late-life
dementia among individuals with a hypercholesterolemic lipid
proﬁle during midlife. There is accumulating evidence from animal
models suggesting a number of biological mechanisms underlying
an effect of dietary fats on dementia. Although the epidemiologic
literature appears mixed for demonstrating the associations be-
tween dietary fatty acid consumption and the risk of developing AD
or dementia, only the CHAP study took into account the con-
founding from different types of fatty acids, which is considerable
and likely contributed to the null ﬁndings in many of the dementia
studies. The CHAP study found an increased risk of AD with higher
consumption of saturated and trans fatty acids and decreased risk
with higher consumption of monounsaturated and poly-
unsaturated fatty acids. A similar pattern emerges from the review
of the studies that investigated the relationship of dietary fatty acid
composition to cognitive decline. However, many more of these
studies adjusted statistically for other fatty acids. Of all the different
types of fatty acids, the ﬁndings are most consistent for an
increased risk of cognitive decline with a higher intake of saturated
fatty acids.
Future studies of fatty acid composition and dementia can best
inform the ﬁeld by analyzing data adjusting for the different types
of fatty acids. Further, primary analyses of these data should be
presented without statistical adjustment of cardiovascular condi-
tions given the established effects of dietary fatty acid composition
on these conditions. Statistical control for these intermediary fac-
tors would result in the underestimation of the effects of dietary
fatty acids on dementia. Also, interpretation of ﬁndings across
studies would be optimized by presentation of the analyses with
fatty acids modeled in quintiles along with the range of intake for
the quintiles in both grams per day and percent energy. This would
allow for determination of the levels of intake at which a particular
fatty acid results in a beneﬁt or risk of dementia. Much more
research is required to understand whether and to what extent
dietary fatty acid composition is related to the development of
dementia and the biological mechanisms that underlie these
relationships.
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